Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Alison Bryant (email | Twitter) and we will feature it...
NewLink Genetics presented updates on its cancer vaccines, HyperAcute Pancreas (algenpantucel-L) and HyperAcute Lung (tergenpumatucel-L), at the American Society of Clinical Oncology 2012 Annual Meeting.
Pancreatic cancer is hard to treat, but adding a cancer vaccine to standard chemotherapy could boost survival.
The Scientist takes a crack at covering the few courageous--or is it foolhardy?--biotech companies willing to go public these days. Steven Burrill notes that there's no appetite for risk, echoing...
It's worth letting out a "hooray" when a biotech does an initial public offering. NewLink Genetics, a cancer vaccine developer, made its public debut today, raising about $43.4 million through the
An Iowa-based biotech named NewLink Genetics is gambling that its late-stage therapeutic cancer vaccine can light a fire under investors as it sets out to garner up to $66 million from an IPO.
NewLink Genetics in Ames, Iowa, has grabbed $7.5 million in a Series D financing designed to accelerate the clinical development of its therapeutic cancer products. The financing involved additional